Stoke Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Stoke Therapeutics, Inc. | STOK - NASDAQ |
$14.00-$16.00 | $18.00 | $27.21 | 7.9 million | 6/19/2019 |
| JP Morgan, Cowen, Credit Suisse | ||||||
Co-Manager(s): Canaccord Genuity | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-05-23 Terms Added 2019-06-07 | ||||||
Stoke Therapeutics, Inc. Quote & Chart - Click for current quote - STOK
IPO Boutique aggregates information on public companies and private companies, such as "STOK" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Stoke Therapeutics, Inc. (adapted from Stoke Therapeutics, Inc. prospectus):
They are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "STOK" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.